AstraZeneca and its hematology research and development center of excellence, Acerta Pharma, said the FDA has granted accelerated approval to Calquence (acalabrutinib, previously known as ACP-196), a kinase inhibitor, for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.
Howard Hughes Medical Institute Investigator David R. Liu was awarded the 2025 Breakthrough Prize in Life Sciences for developing two gene-editing technologies—known as base editing and prime editing—which enable the correction or replacement of virtually any genetic mutation, including those that cause countless human genetic diseases.Â
